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Trabectedin and Zalypsis are two potent anticancer
tetrahydroisoquinoline alkaloids that can form a
covalent bond with the amino group of a guanine in
selected triplets of DNA duplexes and eventually
give rise to double-strand breaks. Using well-defined
in vitro and in vivo assays, we show that the resulting
DNA adducts stimulate, in a concentration-depen-
dent manner, cleavage by the XPF/ERCC1 nuclease
on the strand opposite to that bonded by the drug.
They also inhibit RNA synthesis by: (1) preventing
binding of transcription factors like Sp1 to DNA,
and (2) arresting elongating RNA polymerase II at
the same nucleotide position regardless of the strand
they are located on. Structural models provide
a rationale for these findings and highlight the simi-
larity between this type of DNA modification and an
interstrand crosslink.
INTRODUCTION
Onemajor challenge in cancer therapeutics is to characterize the
altered biochemical pathway in the tumor cell that can be selec-
tively targeted by drugs. Many clinically used antineoplastic
agents cause DNA damage, and their action is influenced by
their ability to specifically disturb fundamental DNA metabolic
processes such as replication, repair, and transcription (Busta-
mante et al., 2011).
Trabectedin (Yondelis, ecteinascidin-743), a compound
originally extracted from the marine tunicate Ecteinascidia
turbinata (Rinehart et al., 1990) and commercially prepared
nowadays by semisynthesis frommicrobially produced cyanosa-
fracin (Cuevas and Francesch, 2009), and Zalypsis, a molecule
structurally related to jorumycin and renieramycins (Scott and
Williams, 2002), are two tetrahydroisoquinoline alkaloids (Figures
1A and 1B) endowed with potent anticancer activities. Trabecte-
din is currently used for the treatment of advanced soft tissue
sarcoma and, in combination with pegylated liposomal doxoru-988 Chemistry & Biology 18, 988–999, August 26, 2011 ª2011 Elsevibicin, relapsed platinum-sensitive ovarian cancer (D’Incalci
and Galmarini, 2010). Zalypsis is particularly effective against
leukemia and stomach tumor cell lines (Leal et al., 2009), is in
phase II clinical trials (Oku et al., 2003), and appears to be prom-
ising for the treatment of multiple myelomas (Ocio et al., 2009).
Both drugs bind covalently to the exocyclic 2 amino group of
a central guanine (G) in selected triplet sequences of double-
stranded DNA (dsDNA). Thus, the adducts are located in the
DNA minor groove (Leal et al., 2009; Pommier et al., 1996;
Zewail-Foote and Hurley, 1999), where the drugs also establish
additional noncovalent interactions with the sugar-phosphate
backbone and other nucleobases in both the strand containing
the adduct (AS) and the complementary, opposite strand (OS),
of the same duplex. As a result, the drug-induced lesion has
been suggested to functionally mimic an interstrand crosslink
(ICL), a type of DNA damage that is highly effective in blocking
replication and transcription (Casado et al., 2008; De Silva
et al., 2000). ICL resolution occurs through the coordinated
action of multiple DNA repair pathways (McHugh et al., 2001),
including nucleotide excision repair (NER) and homologous
recombination (HR), in a process that involves double-strand
breaks (DSBs). Interestingly, exposure of cells to trabectedin
(Casado et al., 2008; Guirouilh-Barbat et al., 2008; Soares
et al., 2007; Tavecchio et al., 2008) or Zalypsis (Guirouilh-Barbat
et al., 2009; Leal et al., 2009; Ocio et al., 2009) results in the
generation of DSBs, as assessed by g-H2AX and Rad51 foci
formation. Moreover, HR-deficient Fanconi anemia cells are
extremely sensitive to trabectedin (Casado et al., 2008). On the
contrary, trabectedin is more cytotoxic in NER-proficient cells
than in their NER-deficient counterparts, particularly those
harboring deficiencies in the XPG and XPF endonucleases,
XPB helicase, and/or ERCC1, the partner of XPF (Damia et al.,
2001; Takebayashi et al., 2001; Zewail-Foote et al., 2001).
Furthermore, it was shown that pharmacological concentrations
of trabectedin can inhibit expression of many NF-Y targeted
genes including those encoding the multidrug resistance efflux
pump MDR1 (Jin et al., 2000) and the molecular chaperone
HSP70 (Minuzzo et al., 2000) as well as several cell cycle regula-
tors such as the Sp1-regulated p21 gene (Friedman et al., 2002).
It is currently unknown whether Zalypsis affects RNA synthesis.
To gain further insight into the mechanism of action of these
two antitumor tetrahydroisoquinolines, we investigated theirer Ltd All rights reserved
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Figure 1. Cytotoxic Effects of Trabectedin and Zalypsis
Structures of trabectedin (A) and Zalypsis (B).
(C) Real-time PCR analysis of RARb2 induction by t-RA from HeLa
cells pretreated with different concentrations of trabectedin (dark
gray) and Zalypsis (light gray). The fold activation (noninduced versus
induced) is shown, and RARb2 mRNA was normalized to GAPDH
mRNA levels.
Table 1. Growth Inhibitory Activities of Trabectedin and Zalypsis
on Different Cancer Cell Lines
Tissue Type Cell Line
IC50 (nM)
a
Trabectedin Zalypsis
Liposarcoma SW872 0.5 0.8
Ewing sarcoma A673 1.0 0.4
Osteosarcoma Saos-2 0.1 0.9
Breast cancer MCF7 2.6 1.8
Ovarian cancer A2780 3.1 1.1
Tumor cells were seeded in 96-well trays and incubated with serial dilu-
tions of each drug for 72 hr.
aHalf-maximal inhibitory concentration.
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By using a bead-immobilized SV40 promoter-containing DNA
template, we explored whether trabectedin can compete with
the transcription factor Sp1 for binding to its responsive
elements and, therefore, prevent the accurate positioning of
the transcription machinery around the promoter. We next
assessed, by means of another bead-immobilized tailor-made
oligonucleotide containing a single CGG triplet (a favored site
for trabectedin and Zalypsis covalent bond formation) (Pommier
et al., 1996), whether these drugs can inhibit RNA synthesis
by preventing the formation of the preinitiation transcription
complex and/or by blocking RNA polymerase II (RNA pol II) elon-
gation (independently of the strand to which the drug is bonded),
and we sought confirmation in HeLa cells. We also tested
whether adducts formed by these drugs can be recognized by
defined components of the NER machinery. Finally, computer
modeling and molecular dynamics (MD) simulations help us to
rationalize our experimental observations.
RESULTS
Antitumor Activities and Effects on Gene Expression
of Trabectedin and Zalypsis
The growth inhibitory activity of the two drugs was evaluated in a
panel of sarcoma (SW872, A673, and Saos-2), breast (MCF7),
and ovarian (A2780) cancer cell lines. All the cancer cell lines
tested were very sensitive to trabectedin and Zalypsis (Table 1),Chemistry & Biology 18, 988–999,with IC50 values in the high picomolar/low nanomolar
range (0.1–3.0 and 0.4–1.8 nM, respectively). Their effect
on gene expression was studied in HeLa cells by moni-
toring transcription of the RARb2 gene, a retinoic acid-
responsive gene whose expression was induced with
105 M all-trans retinoic acid (t-RA). We observed that
1 hr of exposure to increasing concentrations of trabecte-
din and Zalypsis before incubation with t-RA over 6 hr
led to a dose-dependent inhibition of RARb2 gene
expression. At 100 nM, 70% of RARb2 transcription was
inhibited (Figure 1C).
Trabectedin Competes with the DNA-Binding
Transcription Factor Sp1
DNA-binding transcription factors convey information by
associating to their responsive elements. Thus, we inves-
tigated how these drugs could affect the binding of
Sp1 (Dynan and Tjian, 1983), a ubiquitous transcription
factor that specifically recognizes GC-rich sequences in
many gene promoters. The Sp1-responsive element-
containing SV40 promoter (Mathis and Chambon, 1981)
was 32P labeled, immobilized on magnetic beads, and
incubated with increasing amounts of either Sp1-contain-ing HeLa nuclear extracts (NEs) or trabectedin for 30 min before
being washed to remove any nonspecific DNA-binding mole-
cules. DNase I footprinting showed that increasing amounts of
Sp1 protected the SV40 promoter between 106 and 45 as
well as a stretch closer to the transcription start site, as visual-
ized by the disappearance of the G9 and C10 hypersensitive
sites (HSs) (Figure 2A, lanes 1–4). Trabectedin, which is known
to possess high affinity for several GC-rich triplets (Pommier
et al., 1996), also targets the Sp1-binding sites on the SV40
promoter in a dose-dependent manner, in addition to DNA
sequences located at positions C116 or C119 and G3 or
G7, with a DNase I HS being visible at position G60 (lanes 5–8).August 26, 2011 ª2011 Elsevier Ltd All rights reserved 989
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Figure 2. DNase I Footprinting Assays on
the SV40 Promoter and on DNA Templates
Containing a Unique Drug-Binding Site
(A) The 32P-labeled and immobilized SV40
promoter was incubated with increasing amounts
of either HeLa NE or trabectedin before being di-
gested by DNase I. The Sp1-binding sites are
shown at the right of the gel.
(B) Different rounds of incubation of either HeLa
NE or trabectedin, as indicated at the top of the
panel, were performed on the bead-immobilized
SV40 promoter-containing DNA followed by
DNase I treatment.
The AS/CGG (C) or OS/CCGh (D) was incubated
with increasing drug concentrations and treated
with DNase I. The positions of the HS (A and B) or
the protected nucleotides (C and D) are indicated
(nb: for C and D the G0 is the guanine that is
covalently bonded to the drug).
See also Figure S1.
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drug compete for similar target sites, we set up a challenge
assay based on sequential rounds of incubation of either Sp1
or trabectedin. When the DNA template was first incubated
with Sp1-containing HeLa NE and then with the drug, we990 Chemistry & Biology 18, 988–999, August 26, 2011 ª2011 Elsevier Ltd All rights reservedobserved an extended protection origi-
nated by Sp1 itself (Figure 2B, lanes 4
and 2) and the absence of the drug-
specific HS located at positions G60,
T98, C99, and C101 (compare lanes 4
and 3). This suggests that the drug does
not displace Sp1 from its binding sites
on the DNA template. The converse
experiments, in which the DNA template
was first incubated with the drug and
then with Sp1, showed the same foot-
printing pattern as when the template
was incubated with trabectedin alone
(lanes 7 and 8). Thus, under the condi-
tions employed, trabectedin competes
with the transcription factor Sp1 for tar-
geting specific DNA sequences (see Fig-
ure S1 available online).
Trabectedin and Zalypsis Protect
from DNase I Digestion and Inhibit
RNA pol II Transcription
To learn more about how these anti-
cancer drugs affect RNA synthesis, we
designed a bead-immobilized 32P-
labeled DNA substrate (Riedl et al.,
2003) containing a unique, high-affinity,
adduct-forming site (50-CGG-30) in just
one strand flanked by TAA and ATT
repeats on each side. After 30 min of
exposure to increasing drug concentra-
tions to saturate the high-affinity site, fol-
lowed by extensive washing to removeany unbound molecules, this substrate was treated with DNase
I. The AS/CGG was protected from DNase I digestion from
nucleotides (nt) T4 to T+6, being G0 the guanine to which trabec-
tedin is covalently bonded (Figure 2C, lanes 1–6). The Zalypsis
adduct led to a similar but weaker protection (lanes 7–12). An
Chemistry & Biology
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which associates with either trabectedin or Zalypsis only through
hydrogen bonds and van der Waals interactions involving the
CCGh triplet, was likewise detected from nt A3 to A+4 (Fig-
ure 2D). These data show that the presence of the covalently
bonded drugs in the minor groove of the DNA double helix
specifically protects a CGG triplet and the surrounding nucleo-
tides from DNase I access to both DNA strands. The use of
3- and 10-fold excesses of drug allowed us to confirm that this
was a unique drug-binding site on the whole polynucleotide
chain because no other footprints were apparent at these very
high concentrations.
The effect of these drugs on RNA synthesis was investigated
by performing an in vitro transcription assay using as template
a 50 end bead-immobilized DNA molecule containing the adeno-
virus major late promoter (AdMLP) in front of a G-less cassette
(Figure 3A). Following preincubation with the indicated drug
concentrations and washes to remove the excess of unbound
drug, the beads were incubated with highly purified RNA pol II
and the basal transcription factors TBP, TFIIB, TFIIE, TFIIF,
and TFIIH, together with nucleotide triphosphates (NTPs) with
the exception of GTP. Drug exposure resulted in decreased
synthesis of RNA transcripts compared to controls (Figure 3B).
In these experimental conditions we did not observe the pres-
ence of any shorter RNA transcripts due to premature RNA
synthesis arrest (data not shown). Of note, Zalypsis completely
inhibited transcription at a concentration of 1 mM (lane 10),
whereas a much higher concentration of trabectedin was neces-
sary to abolish transcription entirely (lane 4). This may indicate
that Zalypsis is more potent than trabectedin in inhibiting RNA
synthesis. Altogether, the above experiments suggest that
some drug molecules target the promoter and thereby prevent
formation of the transcriptional preinitiation complex, thus
inhibiting RNA synthesis.
To assay the effects of trabectedin and Zalypsis on transcrip-
tion elongation, we used another 50 end bead-immobilized
substrate containing, in addition to the AdMLP and the G-less
cassette of 96 nt, a 127 nt long DNA sequence encompassing
a CGG triplet at position +113 surrounded by AAT or ATT repeats
(Figure 3A). The CGG drug-binding site was placed either on the
transcribed strand (TS) or the nontranscribed strand (NTS). By
following this strategy one trabectedin or Zalypsis adduct was
placed on either the TS or the NTS DNA strand during RNA pol
II elongation. The CGG/TS template was first incubated with all
transcription components in the absence of GTP. In these condi-
tions RNA pol II paused at the end of the G-less cassette
(+96/+99). After several washes to remove both the remaining
preinitiation complexes and the nonspecifically bound factors,
the immobilized template containing only the elongating RNA
pol II (Riedl et al., 2003; Zawel et al., 1995) was incubated with
increasing drug concentrations. After washing off the excess of
drugs, addition of all NTPs including GTP allowed RNA pol II to
further elongate. We observed that both drugs inhibited full-
length transcription (FLT: +223; Figure 3C, lanes 1–6 and 8–13,
respectively). Zalypsis-dependent FLT inhibition was complete
at a much lower concentration than that required by trabectedin
(lanes 11–12 and 4–5). Furthermore, RNA pol II was blocked
by trabectedin a few nucleotides before the CGG site targeted
by the drug, i.e., at positions +108, +109, and +110 (lane 6),Chemistry & Biology 18, 98whereas Zalypsis arrested RNA pol II at +108 and +109 (lane
13). Another difference was the detection of a Zalypsis-specific
RNA pol II stop site at position +98 (lane 13). This could be ratio-
nalized because this drug, but not trabectedin, binds to the
50-TGT-30 triplet and stabilizes a duplex containing this sequence
(Leal et al., 2009).
Strikingly, whenwe investigated whether RNA pol II elongation
could also be affected by the presence of a trabectedin or
Zalypsis adduct in the CGG/NTS, FLT inhibition was observed
not only at the same drug concentrations but also at the
same nucleotide positions that were identified previously on
the CGG/TS construct (Figures 3C and 3D, compare lanes 5
and 11). This result strongly supports the view that the adducts
formed by either trabectedin or Zalypsis mimic ICLs.
Trabectedin and Zalypsis Promote the 50
XPF/ERCC1-Dependent Incision
We next investigated whether the binding of trabectedin and
Zalypsis to DNA would interfere with NER, given the established
connection between these drugs and several NER factors
(Takebayashi et al., 2001). To examine whether the NER
machinery could eliminate this type of DNA damage, we incu-
bated internally labeled polynucleotides containing a single
drug-binding site with the drugs. After extensive washing, we
added the highly purified NER factors XPC/HR23B, TFIIH,
XPA, RPA, XPG, and XPF/ERCC1 (hereafter XPF) and ATP. In
these conditions we did not observe removal of the damaged
oligonucleotide (data not shown), but rather unexpectedly, we
detected that the OS/CCGh strand was cut at positions A4
and A3, whereas the AS/CGG strand (drug adduct at the under-
lined guanine) was slightly incised at positions T7 and A5 (Fig-
ure 4A, lanes 2 and 6). XPF endonuclease was responsible for
this cleavage because the incision signal was lost in its absence
(lane 7), whereas the OS/CCGh substrate was still cleaved when
XPGwas omitted (lane 8). Furthermore, the OS/CCGh pretreated
with either trabectedin (Figure 4C) or Zalypsis (Figure 4E) was
better cut by XPF in a concentration-dependent manner, but
the AS/CGG template was not significantly cleaved (Figures 4B
and 4D).
We reasoned that the weak XPG-uncoupled XPF-dependent
cut on the drug-free DNA template (Figures 4B and 4D, lanes
1–5) must be due to the particular choice of TAA and ATT repeats
on each side of the CGG target triplet giving rise to a sequence-
dependent deformation of the DNA helix (most likely melting)
that is partially recognized by XPF. This interpretation was sup-
ported by results from MD simulations of a solvated 15-mer in
0.1 M NaCl at 400 K, i.e., under conditions that favor strand
separation. Indeed, initial fraying of the oligomer’s ends was fol-
lowed by splaying and complete melting of the two strands after
200 ns, whereas the base pairs making up the central CGG
triplet in the drug-modified DNAs remained hydrogen bonded
throughout the whole simulation (Figure S2; unpublished data).
We also found that in the presence of replication protein A
(RPA), which plays a role in all DNA metabolic processes
involving ssDNA, the XPF-dependent incision on the OS/
CCGh — that is enhanced by trabectedin — was stimulated still
further (Figure 4F, lanes 15–18). Remarkably, the weak XPF-
dependent cuts observed in the absence of drug on the AS/
CGG template at positions T7 and A5 (lanes 5 and 9), and on8–999, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 991
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Figure 3. Effects of Trabectedin and Zalypsis on Transcription
(A) Scheme of the 50 end-immobilized DNA containing the unique binding site 50-CGG-30. The drug-modified guanine (G) is positioned at +113 bp of the tran-
scription start site (+1) either on the CGG/TS or the CGG/NTS.
(B) The DNA template was incubated with amounts of drug as indicated. Quantification of the +96 and +99 nt long transcripts was performed using the ImageJ
software.
The CGG/TS (C) and the CGG/NTS (D) DNA templates were transcribed in the presence of NTPs except GTP, leading to RNA pol II arrest at the end of the G-less-
cassette. After incubation with increasing amounts of trabectedin and Zalypsis and washing off the unbound drug, transcription was resumed in the presence of
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Antitumor DNA Interstrand Crosslink-Mimetic Drugsthe OS/CCGh at position C1 (lanes 15 and 17), became unde-
tectable at high drug concentrations. This demonstrates how
the drug-modified DNA becomes a suitable substrate for the
XPF endonuclease. In the presence of Zalypsis, we also
observed a dose-dependent stimulation of the OS/CCGh
cleavage (Figure 4F, lanes 20–23). However, the incision located
at position A3 on this strand predominated over that appearing
at position A4 (lanes 22–23) when compared to the results ob-
tained in the presence of trabectedin (lane 17). Interestingly, in
the case of Zalypsis, RPA partially inhibited the XPF-dependent
incision on the OS/CCGh strand. This illustrates that our system
is able to translate the structural differences between the two
drugs into macroscopic observables. Altogether, the above
data show how trabectedin and Zalypsis promote the formation
of a DNA structure that allows a specific 50 XPF-dependent inci-
sion on the OS/CCGh DNA, i.e., the strand opposite to that con-
taining the drug adduct.
Trabectedin and Zalypsis Induce DNA Strand Breaks
In Vivo
The trabectedin- and Zalypsis-dependent induction of DNA
strand breaks was evaluated in HeLa cells using the comet
assay, which is based on the alkaline lysis of labile DNA at sites
of damage (Collins et al., 2008). DNA from cells that have accu-
mulated damage appears as fluorescent comets with tails of
DNA fragmentation or unwinding, whereas normal, undamaged
DNA does not migrate far from the origin (Figure 5A). We next
investigated how the silencing of XPF (using HeLa cells that
stably express siRNA against XPF, HeLa siXPF) would affect
the generation of DNA breaks. Both HeLa siCtrl and HeLa siXPF
cells were treated with trabectedin and Zalypsis at 10 and
100 nM for 15 hr. We observed a clear concentration-dependent
increase in DNA strand breaks in both cell lines following treat-
ment with either drug (Figures 5B and 5C). Of note, HeLa siXPF
cells showed a lower amount of DNA breaks after drug treatment
compared to HeLa siCtrl cells. With trabectedin these differ-
ences were observed only at 100 nM (p < 0.01), whereas with
Zalypsis, they were observed at the two drug concentrations
tested (10 and 100 nM; p < 0.01). Notably, no major differences
in formation of g-H2AX foci, a DSB marker, were found upon
drug treatment in siCtrl and siXPF cells (Figure S3), consistent
with earlier reports for mitomycin C (Niedernhofer et al., 2004).
Altogether, our results suggest that XPF endonuclease is
involved in the formation of drug-induced single-strand DNA
breaks (SSBs).
DISCUSSION
We and others showed that both trabectedin and Zalypsis inhibit
the growth of a variety of cancer cell lines and tumor cells
(D’Incalci and Jimeno, 2003; Leal et al., 2009; Ocio et al., 2009)
(Table 1). However, the cell type-sensitivity pattern for trabecte-
din is different from that observed for Zalypsis because the
former drug shows selectivity against sarcoma, breast, ovarian,
and lung tumor cell lines, with head-and-neck and colon tumorall NTPs including GTP. The RNA transcripts were analyzed on a 5% denaturing
performed. Trabectedin or Zalypsis-mediated stops were detected close to the 5
indicated in brackets on the sequence on the right of each gel.
Chemistry & Biology 18, 98cells being slightly less sensitive, whereas the latter is more
potent against leukemia and stomach tumor cell lines, with
breast cancer cells being slightly less sensitive than the average
(Koeppel et al., 2004; Poindessous et al., 2003). The aim of the
present work is to improve our understanding of the particular
and specific mode of action of these drugs and highlight any
differences between the two.
Trabectedin and Zalypsis Mimic ‘‘DNA Interstrand
Crosslinkers’’
The first step in the binding of a typical bifunctional agent to
DNA is the formation of a monoadduct, and this is followed
by a second reaction, on either the same strand (intrastrand)
or the complementary strand (interstrand), leading to the
formation of a crosslink (Muniandy et al., 2010). By covalently
linking the two complementary strands of the double helix,
ICLs prevent DNA melting, transcription, and replication: hence,
they are considered as themost toxic lesions induced by chemo-
therapeutic agents (Ben-Yehoyada et al., 2009). Because the
thermal stability of a DNA duplex increases substantially by the
presence of a single bonded trabectedin or Zalypsis molecule
(Casado et al., 2008; Leal et al., 2009), this type of monoadduct
could represent the same complex challenge to DNA repair
mechanisms, as does an ICL. Here, we produce additional
evidence that the adducts formed by both trabectedin and
Zalypsis functionally mimic a typical ICL despite the fact that
these drugs bind covalently to only one DNA strand, their
interaction with the OS being only through van der Waals
contacts and hydrogen bonds. These ICL-mimetic properties
were first illustrated by footprinting assays that demonstrated
how the drugs specifically protect the high-affinity CGG
sequence, as well as the complementary triplet in the OS, from
DNase I digestion (Figure 2). The observed differences in the
DNase I footprinting patterns, together with subtly distinct
effects in the transcription and repair assays (Figures 3 and 4),
reflect the structural variations in the drug substituent that
protrudes out of the minor groove in the covalent complexes
formed with dsDNA, i.e., a tetrahydroisoquinoline for trabectedin
(Garcı´a-Nieto et al., 2000) and a trifluorocinnamic moiety for
Zalypsis (Leal et al., 2009). Because these drugs ‘‘interact,’’
albeit in different ways, with both DNA strands, it is not surprising
that NER was ineffective in removing the adducts (data not
shown), contrary to what is seen with UV- or cisplatin-damaged
DNA: neither XPC, XPE, nor XPA would recognize and unwind
the damaged DNA (Aboussekhra et al., 1995). Likewise, XPC is
inefficient in recognizing the highly tumorigenic benzo[a]pyrene
diol epoxide DNA adducts that are known to weaken Watson-
Crick hydrogen bonding and base-base stacking interactions
and give rise to local thermal destabilization of the double helix
(Schinecker et al., 2003).
Trabectedin and Zalypsis Promote DNA Cleavage
by XPF
Further support for the ICL-mimetic properties of the drug-DNA
adducts studied was obtained when we discovered theurea gel, and quantifications of the full-length transcripts (FLT, +223 bp) were
0-CGG-30 containing region (+113 nt). The drug-induced RNA pol II arrests are
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Figure 4. Trabectedin- and Zalypsis-Dependent Effects on DNA Incision
(A) Characterization of the incision on the AS/CGG and the OS/CCGh pretreated with trabectedin and incubated with NER factors in the presence or absence of
XPG and XPF.
XPF-dependent incision on either the AS/CGG or the OS/CCGh in the presence or absence of either trabectedin (B and C) or Zalypsis (D and E). (F) RPA-mediated
effect on the trabectedin (right panel)- and Zalypsis (left panel)-dependent incision using the AS/CGG and the OS/CCGh substrates.
See also Figure S2.
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Figure 5. Trabectedin and Zalypsis Induce DNA Breaks In Vivo
(A) Representative images of damaged DNA in the comet assay in untreated
and trabectedin-treated (for 12 hr) HeLa cells. HeLa siCtrl and HeLa siXPF cells
were analyzed through comet assay followed by exposure to (B) trabectedin
and (C) Zalypsis at 10 and 100 nM during 15 hr. Cells were treated, washed
with PBS, detached mechanically, and included in low melting point agarose.
After lysis, cells were subjected to electrophoresis, and the comets were
stained with SYBR Green. DNA quantitation in the comets was performed with
TriTek CometScore Freeware version 1.5 (p < 0.001). Pictures were taken with
a Leica DM IRM fluorescence microscope equipped with a DFC 340 FX digital
camera (Leica, Wetzlar, Germany). A minimum of 200 cells was analyzed, and
the experiments were repeated in duplicate. The Mann-Whitney U test was
used for the statistical analysis. See also Figures S3 and S4.
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or Zalypsis by XPF, a structure-specific endonuclease that
preferentially cleaves DNA duplexes adjacent to a 30 ss flap
(Mocquet et al., 2007) and that has been shown to recognize
partially unwound structures near a psoralen-induced ICL (de
Laat et al., 1998). Drug-induced DNA strand breaks in living cells
were assessed by the comet assay and g-H2AX staining (Fig-
ure 5; Figure S3). The finding that SSBs decreased following
silencing of XPF expression strongly suggests that the drug-
bonded DNA provides an accurate 3D substrate that is recog-
nized and acted upon by the XPF endonuclease, a key player
in multiple steps of ICL repair (Kuraoka et al., 2000; Soares
et al., 2007).
The extreme sensitivity to trabectedin of HR-deficient cells,
which is similar to that evoked by the minor groove-binding
and ICL-forming mitomycin C (Rahn et al., 2010), is indeed
suggestive that the type of monoadducts formed by these tetra-
hydroisoquinolines can functionally behave like an ICL. In fact
when DNA strand separation is effectively prevented, replication
and transcription forks stall, and this event is known to trigger the
recruitment of XPF/ERCC1, together with RPA, for 50 cleavage of
the damaged DNA. Support for this interpretation was obtained
from MD simulations results, which clearly showed that theChemistry & Biology 18, 98melting of the target oligonucleotide at, and on both sides of,
the central CGG triplet is hampered in the presence of the
bonded drugs (Figure S2). These observations imply that
trabectedin and Zalypsis contribute to extending the length of
the Watson-Crick base-paired central region and, therefore,
enhance XPF recognition and binding by stabilizing a ds/ss
discontinuity and one or two 30 DNA flaps.
To account for the positions of the incisions catalyzed by XPF
when either trabectedin or Zalypsis is bonded to the CGG target
site, we built molecular models of human XPF/ERCC1 in
complex with 50-(TAA)2CGG(ATT)2-30. The DNA-binding domain
(DBD) of ERCC1 recognizes dsDNA, and the nuclease domain of
XPF cuts one strand of this dsDNA at the 50 side of a junction with
ssDNA. The exact cleavage position varies from 2 to 8 nt away
from the junction (Mu et al., 2000), and it appears that the ssDNA
arm protruding in the 30 direction (the ‘‘30-flap’’ or ‘‘30-overhang’’)
is the only requisite for the positioning of the incisions carried out
by XPF/ERCC1. Our modeled structures indicate that two
different cleavable complexes need to be formed to account
for the cuts on either the AS/CGG or OS/CCGh of the DNAmole-
cule, but the observation of an incision only at the OS/CCGh
indicates that only one is feasible in the presence of the drugs
(Figure 4). We note that to cleave the AS/CGG, the required
ssDNA region favored by the TA surroundings could start
forming at the first A located 30 to the central CGG dsDNA
stretch. However, the presence of a drug molecule covalently
bonded to the middle (underlined) guanine in this triplet
hampers DNA melting and, hence, cutting of this strand by the
nuclease, which cannot find the mandatory 30 flap. On the
contrary, the ssDNA region in the OS can start forming following
the T placed 30 to the CCGh triplet, whereas the dsDNA stretch
will comprise the central CGG/CCGh plus a variable number
of paired bases 50 to the first C (in CCGh) that is longer for the
trabectedin adduct, and shorter for the Zalypsis adduct (Figures
6A and 6B). Of note, the structural differences between the
two drugs studied here are also found in this region, with trabec-
tedin establishing an additional H bond between the phenolic
oxygen in the protruding tetrahydroisoquinoline and the phos-
phodiester backbone (Garcı´a-Nieto et al., 2000) and Zalypsis
sticking out a trifluorocinnamic moiety into the solvent/protein
environment.
Although the comet assay showed that the SSBs depended on
XPF (Figure 5), the silencing of individual NER factors (XPG or
XPF/ERCC1) rendered the cells neither resistant nor hypersensi-
tive to these drugs (Figure S4). These observations suggest that
inducing the XPF-dependent DNA cuts is not the main cytotoxic
mechanism harnessed by these drugs and that their activity
should follow an alternative pathway.
Trabectedin and Zalypsis Inhibit RNA pol II Transcription
Finally, extra support for the ICL-mimetic hypothesis was gained
when we showed that DNA damage caused by both drugs
obstructs the expression of activated genes (Figure 1). The
binding of these drugs to particular sequence triplets, located
within certain responsive elements of the promoter of a given
gene, might prevent the formation of the transcription complex.
This was documented by challenge experiments between tra-
bectedin and the transcription factor Sp1 competing to bind to
GC-rich sites (Figure 2; Figure S1). Our results additionally8–999, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 995
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Figure 6. Impact of Trabectedin and Zalyp-
sis on DNA Incision and Transcription
Processes
Trabectedin (A) and Zalypsis (B) stimulate an XPF-
dependent incision on the OS/CCGh, i.e., the
strand opposite to that harboring the drug
adducts. Trabectedin (C) and Zalypsis (D) block
RNA pol II progression when the drug is located
either on the TS or the NTS. Only the complex
structure containing the longest possible RNA
transcript is represented for each drug. The
schematic representation of RNA pol II is based on
Figure 4 from Cramer (2004).
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stalling regardless of whether the covalent adduct is present
on the TS or the NTS (Figure 3). Such property supports the996 Chemistry & Biology 18, 988–999, August 26, 2011 ª2011 Elsevier Ltd All rights reservedICL-mimetic behavior of the drug-DNA
adducts, which likely underlies the potent
cytotoxicity of these compounds, and is
in stark contrast with observations made
for other adducts (de Laat et al., 1998),
which do not have such an effect on tran-
scription elongation when placed on the
NTS. It must be kept in mind that
the foremost DNA adduct for cisplatin is
the 1,2-GG intrastrand crosslink and
that less than 8% of cisplatin lesions
consist of ICL (Frit et al., 2002; Schi-
necker et al., 2003). Therefore, the major
difference between these two types of
adducts is that the key lesion involving
cisplatin affects the major groove of
two contiguous guanines in the same
strand, whereas in the case of the minor
groove-binding tetrahydroisoquinolines
studied here, the presence of the cova-
lently bonded drug affects both strands
and stabilizes the duplex structure. As
a consequence, DNA strand separation
is hampered regardless of which strand
bears the lesion, and RNA pol II is
arrested during transcription elongation.
This finding could be relevant to the
mechanism of cytotoxicity exerted by
these drugs.
From the structural point of view, we
provide an explanation in atomic detail
for the differential arrest of RNA pol II
synthesis (Figures 6C and 6D) in light of
available crystal structures of RNA pol II
elongation complexes (Huang et al.,
1995; Stehlikova et al., 2002). Indeed,
the number of base pairs between the
drug adducts and the ssDNA-RNA
hybrid past the polymerase active site
was found to be slightly different in the
modeled complexes involving each sepa-rate drug and to be in good accordance with the distinct sizes
obtained for the RNA transcripts. Thus, three alternative models
for the trabectedin-DNA-RNA pol II complex are possible,
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guanine with respect to the active site, but only two in the case
of Zalypsis due to the extended protrusion of the trifluorocin-
namic moiety giving rise to steric clashes with the protein and
precluding further movement of RNA pol II along the DNA
template. For simplicity we present only one structure of the
putative complex containing the DNA-bonded drug and the
longest possible RNA transcript (Figures 6C and 6D). Because
translocation over the bridge helix is prevented due to the pres-
ence of the drug on either strand, completion of the next nucle-
otide addition cycle is not feasible, and the RNA transcript is
prematurely terminated.
In conclusion our study shows that the anticancer compounds
trabectedin and Zalypsis, upon binding to DNA, give rise to
a lesion that functionally mimics an ICL even though these drugs
are covalently linked to only one DNA strand. These drugs
promote XPF/ERCC1-dependent DNA breaks, inhibit RNA
synthesis regardless of which DNA strand contains the adduct,
and may prevent binding of Sp1, as shown here, and/or other
transcription factors. However, it still remains to be seenwhether
these ICL-mimicking adducts can also preclude or stimulate the
recruitment of one or more of the HR proteins that are likely to
participate in the removal of these covalent modifications from
damaged DNA.
SIGNIFICANCE
Exposure of cells to trabectedin or Zalypsis eventually gives
rise to DNA double-strand breaks that do not originate
directly from drug binding to the amino group of selected
guanines in the minor groove of DNA but are formed during
the processing of the resulting covalent adducts by the DNA
repairmachinery. Intriguingly, cells defective in homologous
recombination (HR) repair are particularly sensitive to these
agents, whereas cells deficient in nucleotide excision repair
(NER) aremore resistant to trabectedin than their NER-profi-
cient counterparts. Using well-defined in vitro and in vivo
assays, we now show that the DNA adducts formed by these
two potent anticancer agents are not removed by the NER
machinery, although the XPF/ERCC1 nuclease is able to
cleave the strand opposite the lesion in a drug-dependent
way. Furthermore, these adducts compete with DNA-
binding factors like Sp1 for their specific DNA-binding sites
and also arrest elongating RNA polymerase II at the site of
the lesion regardless of whether the compounds are cova-
lently attached to the template or the nontemplate strand.
All of these results, which are supported by structural
models, are consistent with the view that a single adduct
formed by any of these drugs in just one DNA strand can
functionally mimic an interstrand crosslink insofar as it can
hamper or prevent repair and strand separation very effec-
tively. Therefore, it would seem that stalling transcription
and replication forks is likely to be a hallmark of the antipro-
liferative action of these tetrahydroisoquinoline alkaloids.
Moreover, identification of the genes involved in their
mechanism of action, and particularly in the DNA damage
response, that are deregulated in a given tumor may help
to select the subsets of patients that will benefit the most
from this type of chemotherapeutic agent.Chemistry & Biology 18, 98EXPERIMENTAL PROCEDURES
Activated Transcription
HeLa cells were grown to 50% confluency before being subjected to media
containing charcoal-treated FCS (10%) and devoid of phenol red for 16 hr.
Then, cells were pretreated for 1 hr with either drug, before t-RA induction
(10 mM for 6 hr). Reverse transcription was done using 1 mg of total RNA
(GenElute Mammalian Total RNA Miniprep Kit; Sigma-Aldrich), oligo-dT(15),
and SuperScript II Reverse Transcriptase (Invitrogen).
Design of the DNA Templates
The SV40 promoter was PCR amplified from pGL3 vector (Promega) using a 50
radioactively labeled primer with Optikinase (USB Corp.) and 100 nM g32P-
dATP (6000 Ci/mmol), a biotinylated primer, and resolved on a 5% native 13
TBE polyacrylamide (PAA) gel. The DNA substrates containing a single CGG
site for drug binding were generated by heating the forward (A[TAA]20CGGAT
TATT) and the reverse (AA[TAA]20CCGTTATT) primers at 95
C for 5 min and
slowly cooling down to 4C. The Klenow fragment was used for fill-in synthesis
during 30 min at 25C in the presence of 1 mM dNTPs. The purified amplicon
(QIAGEN PCR) was cloned into pGEM-T plasmid (Invitrogen) leading to
pGEM-T 1xCGG containing the following sequence: AT(TAA)13CGG(ATT)19T.
The AS/CGG and the OS/CCGh-labeled templates were generated by digest-
ing 100 mg pGEM-T 1xCGG using SpeI for AS/CGG, and NcoI for OS/CCGh
(50 U for 3 hr). Biotinylated and radioactive nucleotides were filled in using
30 U Klenow fragment, 50 mM dATP/dGTP, 20 mM Biotin-16-dUTP (Roche
Diagnostics), and 130 nM a32P-dCTP (3000 Ci/mmol) (GE Healthcare) at
37C, followed by a second enzyme digestion (NcoI for AS/CGG and SpeI
for OS/CCGh) overnight at 37C. The probe was resolved on an 8% native
PAA gel.
The pBL-CAX TS.500 (Charlet-Berguerand et al., 2006) was digested by
XbaI and SalI. A G-less cassette was PCR amplified (Sawadogo and Roeder,
1985) using High Fidelity polymerase (Roche), the XbaI-restriction site contain-
ing specific primers, and then digested by XbaI and SalI, gel purified, and
ligated using NEB’s Quick Ligation Kit protocol. The remaining G in the XbaI
restriction site was changed to a C by performing site-directed mutagenesis
using Phusion polymerase (Finnzymes) and specific primers. After gel purifica-
tion, the PCR amplicon was ligated using T4 ligase (NEB) leading to the pBL-
Gless96-CAX TS.500.
To insert the single drug-binding site into the pBL-G-less96-CAX TS.500, we
deleted the sequence located after the G-less cassette using primers with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene). Then, we inserted
the single drug-binding triplet into the plasmid using primers leading to the
pBL-Gless96-CAX TS.500 CGG/TS and pBL-Gless96-CAX TS.500 CGG/NTS.
DNase I Footprinting Assays
The 50 end 32P-labeled (20,000 cpm) SV40 promoter template was immobilized
on 2.01 3 105 magnetic beads (Dynabeads), incubated for 30 min at RT in
buffer A (Tris/HCl 10 mM [pH 7.6], glycerol 10%, EDTA 1 mM, DTT 0.5 mM,
KCl 50 mM, and 0.05% NP40), and then incubated either with 1–5 mg/ml of
HeLa Sp1 containing NE or with 10–20 mM trabectedin for 30 min. For
the competition assay the above substrate was incubated first with either
3 mg/ml of NE or 20 mM trabectedin for 30 min, and vice versa in a second incu-
bation. Low-salt concentration washes were then performed to remove any
DNA-unbound molecules before subjecting the DNA template to digestion
using 1 ng/ml DNase I (Sigma-Aldrich) for 45 s at RT in buffer A supplemented
with 5 mM MgCl2, and 20 mg/ml polydI-dC.
The 30 end-labeled (20,000 cpm) pGEM-T 1xCGG-derived AS/CGG or the
OS/CCGh substrates were bound to magnetic beads and treated with the indi-
cated drug concentrations. Unspecific bound molecules were removed by
gently washing with buffer A before DNase I digestions. The reaction was
stopped, and the purified nucleic acids were resolved on an 8% denaturing
urea-PAA gel.
In Vitro Transcription
The immobilized pBL-Gless96-CAX TS.500 CGG/TS or the pBL-Gless96-CAX
TS.500 CGG/NTS PCR-amplified product was incubated with the drug. After
extensive washing, the template was incubated with all the basal transcription
factors including RNA pol II for 30 min at 25C (Charlet-Berguerand et al.,8–999, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 997
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Ci/mmol) were added for 30 min at 25C.
For the investigation of the drugs’ effects on transcription elongation, the
template was first incubated with all the basal transcription factors and rNTPs
except GTP. After extensive washes (Riedl et al., 2003), the ternary elongation
complex was incubated for 30 min with the drug in buffer A containing rNTPs
(in the absence of GTP). After washes with buffer A, 300 mM rNTPs and 6.5 mM
MgCl2 were added. Nucleic acids were analyzed on a 5% denaturing urea-
PAA gel.
Comet Assay
For the comet assay a single-cell gel electrophoresis assay was used
(Trevigen’s CometAssay) following the manufacturer’s instructions after treat-
ment of cells for 12 hr with the appropriate concentration of trabectedin and
Zalypsis. Pictures were taken with a Leica DM IRM fluorescence microscope
equipped with a DFC 340 FX digital camera (Leica, Wetzlar, Germany).
Quantitation of the DNA in the tails of the comets was performed with Adobe
Photoshop CS3 (Adobe Systems Inc., San Jose, CA). For each condition
30 cells were analyzed, and the experiments were repeated several times.
Molecular Modeling
XPF/ERCC1 in Complex with Drug-Bound DNA
The nuclease domain of human XPF was modeled using the coordinates of
Pyrococcus furiosus Hef as a template (PDB ID: 1J23) and the sequence align-
ment (Kelley and Sternberg, 2009). The resulting structure and the DBDs of
XPF and ERCC1 (PDB ID: 2A1J) were superimposed onto their DBD counter-
parts in the Aeropyrum pernix XPF homodimer in complex with dsDNA (PDB
ID: 2BGW). The root-mean-square deviation between the Ca traces of human
and crenarchaeal XPF nuclease domain was 1.1 A˚, whereas that between their
DBDs was 1.26 A˚ (53 atoms). The A. pernix XPF-dsDNA structure comprises
two XPF protomers and one DNA duplex, bound to the nuclease and (HhH)2
domains of the first protomer (site I). Because the (HhH)2 domain of the second
protomer (which corresponds to ERCC1) is also potentially capable of binding
DNA (site II), a second dsDNA molecule was built at 90 to the experimentally
observed dsDNA using a symmetry operator on the DNA in the unit cell as
reported in Newman et al. (2005). The DNA-drug adducts were modeled as
reported for trabectedin in PDB/OCA entry 1EZH (Garcı´a-Nieto et al., 2000).
Drug-DNA-RNA Pol II Elongation Complex
The crystal structure of the RNA pol II elongation complex (Sydow et al., 2009),
containing both a DNA template and an RNA transcript (PDB ID: 3HOV), was
used upon appropriate substitution of DNA bases so as to model the oligonu-
cleotide employed in our experiments. The position of the CGG triplet to which
trabectedin and Zalypsis bind in relation to the polymerase active site was
systematically varied stepwise to define those locations in which the drug
would give rise to steric clashes with the protein. All primer sequences are
available upon request.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
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